<DOC>
	<DOCNO>NCT01348880</DOCNO>
	<brief_summary>The study conduct multi-center , randomize , double-blinded , placebo control , crossover design . The investigational drug ( vardenafil ODT ( Orally Disintegrating Tablet ) /placebo ) give single administration dose 10 mg vardenafil ODT Period 1 2 ; blind match placebo give single administration oppose period . The random code determine order active drug ( vardenafil ODT ) placebo subject . Blood pressure heart rate profile record automated device pre-dose 8 hour post-dose Periods 1 2 . The non investigational drug product ( vasodilator ) , Procardia XL , background treatment hypertension , take daily subject . All subject must stable vasodilator least 4 week prior Day 1 Period 1 . Special condition study include requirement subject male , age 65 80 year , diagnosis erectile dysfunction ( ED ) , well hypertension . Planned sample size 40 subject evaluable primary analysis . Of 40 subject valid analysis , 20 age 65 69 year , 20 subject age 70 80 year . The total duration study approximately one year first subject treat last subject treat , include replacement subject fail complete period crossover dose .</brief_summary>
	<brief_title>Vardenafil ODT ( Orally Disintegrating Tablet ) - Nifedipine Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Subjects must fulfill follow criterion include treatment period i.e. , receive dose study relate medication ( Sponsor supply Procardia XL , vardenafil Orally Disintegrating Tablet ( ODT ) /placebo tablet ) : The informed consent must sign study specific test procedures do Male gender Diagnosis essential hypertension ( HTN ) erectile dysfunction ( ED ) High blood pressure , hypertension , define adult systolic pressure 140 mm Hg high and/or diastolic pressure 90 mm Hg high . As stated current American Heart Association guideline . Documented ED 6 month accord National Institutes Health ( NIH ) Consensus statement ( inability achieve maintain penile erection sufficient satisfactory sexual performance ) . The diagnosis ED confirm use fiveitem version ( Rosen RC ) International Index Erectile Function ( IIEF5 ) , see Appendix 14.4 . The total IIEF5 score must least 8 , exceed 19 . Subjects must use least one Phosphodiesterase5 ( PDE5 ) inhibitor , Viagra , Levitra Cialis time prior entry study . Age : 65 80 year ( inclusive ) first screen examination / visit Body mass index ( BMI ) : above/equal 18 below/equal 32 kg / mÂ² Subjects exclude study display follow criterion : Medical surgical history Preexisting diseases assumed absorption , distribution , metabolism , elimination effect study drug normal . This include severe renal impairment ( dialysis ) moderate severe hepatic disease . Known hypersensitivity calcium channel blocker ( active substance excipients tablet preparation ) Known hypersensitivity PDE5 inhibitor , Viagra , Levitra Cialis ( active substance instance , excipients tablet preparation consider possible allergen , e.g. , lactose , aspartame ) Known severe allergy , nonallergic drug reaction , multiple drug allergy Recent history ( within 6 month ) myocardial infarction ( MI ) , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , cerebrovascular accident ( CVA ) Known leave ventricular outflow syndrome ( LVO ) History significant coronary artery disease , e.g. , angina Congenital acquire prolonged QT syndrome Congestive heart failure ( CHF ) [ NYHA Class 3 4 ] History adult epilepsy seizure disorder History retinitis pigmentosa Use antihypertensive medication calcium channel blocker , Procardia XL ( nifedipine ) , supply sponsor , study Any drug know induce cytochrome P450 ( CYP ) enzymes ( eg rifampicin , carbamazepine , phenytoin , bosentan , dexamethasone , barbiturate , St. John 's Wort [ hypericum perforatum ] ) Any drug know inhibit CYP enzymes : specifically potent moderate cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) inhibitor HIV protease inhibitor ( e.g . ritonavir , indinavir , saquinavir , atazanavir ) , ketoconazole , itraconazole , clarithromycin erythromycin Use nitroglycerin form nitrate allow All alphablockers ( e.g. , Hytrin , Flomax , Uroxatral ) prohibit Electrocardiogram ( ECG ) , blood pressure , heart rate Clinically relevant finding ECG second thirddegree AV block , prolongation QRS complex 120 msec QTcinterval 450 msec Systolic blood pressure 110 150 mmHg antihypertensive therapy Diastolic blood pressure 60 95 mmHg antihypertensive therapy Heart rate 40 95 beat / min antihypertensive therapy Serum creatinine &gt; 2.5 mg/dL Screening HbA1c &gt; 8 % indicative uncontrolled DM Screening</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>drug-drug interaction</keyword>
</DOC>